Imbalance between MMP-2, 9 and TIMP-1 promote the invasion and metastasis of renal cell carcinoma via SKP2 signaling pathways

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 9807-9813

  Lu, Hongsheng ^a   Cao, Xuequan ^a   Zhang, Hui ^a   Sun, Gang ^a   Fan, Guangmin ^a   Chen, Lili ^a   Wang, Siling ^a  

^a Central Hospital of Taizhou   (China)

Author keywords

Invasion .MMP 2 .MMP 9; SKP2; TIMP 1

Indexed keywords

GELATINASE A; GELATINASE B; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; S PHASE KINASE ASSOCIATED PROTEIN; SMALL INTERFERING RNA; TIMP1 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; IMMUNOBLOTTING; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; S-PHASE KINASE-ASSOCIATED PROTEINS; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFECTION;

EID: 84922393937     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2256-7     Document Type: Article

References (20)

1. Hung WC, Tseng WL, Shiea J, Chang HC. Skp2 overexpression increases the expression ofMMP-2 andMMP-9 and invasion of lung cancer cells. Cancer Lett. 2010; 288: 156-61.
2. Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J. 2000; 19: 2069-81.
3. Wei Z, Jiang X, Liu F, QiaoH, Zhou B, Zhai B, et al. Downregulation of Skp2 inhibits the growth and metastasis of gastric cancer cells in vitro and in vivo. Tumour Biol. 2013; 34: 181-92.
4. Yang G, Ayala G, DeMarzo A, TianW, Frolov A, Wheeler TM, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 2002; 8: 3419-26.
5. Abdou AG, Asaad NY, Abd El-WahedMM, SamakaRM, Allah MS. The prognostic value of Skp2 expression in Egyptian diffuse large Bcell lymphoma. Appl Immunohistochem MolMorphol. 2012; 20: 47-55.
6. Liu Z, Fu Q, Lv J, Wang F, Ding K. Prognostic implication of p27Kip1, Skp2 and Cks1 expression in renal cell carcinoma: a tissue microarray study. J Exp Clin Cancer Res. 2008; 27: 51.
7. Fisher JF, Mobashery S. Mechanism-based profiling of MMPs. Methods Mol Biol. 2010; 622: 471-87.
8. Langner C, von Wasielewski R, Ratschek M, Rehak P, Zigeuner R. Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique. Virchows Arch. 2004; 445: 631-6.
9. Struckmann K, Mertz K, Steu S, Storz M, Staller P, Krek W, et al. pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J Pathol. 2008; 214: 464-71.
10. Moore CS, Crocker SJ. An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol. 2012; 180: 12-6.
11. Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Jung K. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas. Cancer Sci. 2008; 99: 1188-94.
12. Lu H, Yang Z, Zhang H, Gan M, Zhou T, Wang S. The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma. Exp Ther Med. 2013; 5: 890-6.
13. Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M. S-phase kinase-associated protein 2 expression in laryngeal squamous cell carcinomas and its prognostic implications. Oncol Rep. 2003; 10: 321-5.
14. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Asp Med. 2008; 29: 290-308.
15. Di Carlo A. Matrix metalloproteinase-2 and-9 and tissue inhibitor of metalloproteinase-1 and-2 in sera and urine of patients with renal carcinoma. Oncol Lett. 2014; 7: 621-6.
16. Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem. 1999; 274: 29130-7.
17. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2: 737-44.
18. Tapias A, Ciudad CJ, Roninson IB, Noe V. Regulation of Sp1 by cell cycle related proteins. Cell Cycle. 2008; 7: 2856-67.
19. Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer. 1997; 70: 722-6.
20. Zhang X, Wang Y, Yamamoto G, Tachikawa T. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 in the epithelium and stroma of salivary gland pleomorphic adenomas. Histopathology. 2009; 55(3): 250-60.